EXHIBIT 10.1

  

CONFIDENTIAL TREATMENT REQUESTED

 

CERTAIN CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE BEEN REDACTED BECAUSE THEY
ARE BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY
DISCLOSED. INFORMATION THAT WAS OMITTED HAS BEEN NOTED IN THIS DOCUMENT WITH A
PLACEHOLDER IDENTIFIED BY THE MARK “[***]”.

 

FIRST AMENDMENT TO MATERIAL AND DATA TRANSFER, OPTION AND LICENSE AGREEMENT

 

THIS FIRST AMENDMENT TO MATERIAL AND DATA TRANSFER, OPTION AND LICENSE AGREEMENT
(this “Amendment”) is made and entered as of January 4, 2019 (“Amendment
Effective Date”), by and between NEOMED Institute, a not-for-profit corporation
established under the Not-for-Profit Corporations Act (Canada), having an
address at 7171 Frederick-Banting, Saint-Laurent, Quebec H4S 1Z9, Canada
(“NEOMED”), and Artelo Biosciences, Inc., a Nevada corporation, having an
address at 888 Prospect Street, Suite 210, La Jolla, California 92037, U.S.A.
(“Artelo”).

 

WHEREAS, NEOMED and Artelo are parties to that certain Material and Data
Transfer, Option and License Agreement dated as of December 20, 2017 (the
“Agreement”); and

 

WHEREAS, NEOMED and Artelo wish to amend the Agreement to take into account,
among such other changes set forth below, the additional cash and equity
consideration to be paid by Artelo in partial consideration for the waiver by
NEOMED of the payment of the amount of One Hundred Thousand Dollars (US$100,000)
in cash that was due NEOMED on October 1, 2018 under the Agreement.  All
capitalized terms used in this Amendment which are not otherwise defined herein
shall have the same meanings as set forth in the Agreement.

 

NOW, THEREFORE, in consideration of the foregoing premises, the mutual covenants
and promises contained in this Amendment and other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged,
NEOMED and Artelo agree as follows:

 

1.       Amendments to the Agreement. 

 

a.       Section 3.1 of the Agreement is hereby amended and restated to read in
its entirety as follows:

 

“3.1     Option Grant.  For a period commencing on the Effective Date and
subject to early termination, ending on [***] (“Option Period”), Artelo shall
have the sole and exclusive right, but not the obligation to receive an
exclusive license under the Licensed IP Rights to research, develop, make, have
made, use, offer for sale, sell, have sold and import Products and otherwise
exploit the Licensed IP Rights in the Territory in the Field, subject to the
terms and conditions of this Agreement (the “Option”).  During the Option
Period, NEOMED shall not, without Artelo’s prior written consent, directly or
indirectly: (i) negotiate or enter into any agreement, arrangement or commitment
according to which a Third Party is granted any right in the Territory under the
Licensed IP Rights, (ii) take any action which may derogate from or conflict
with, or refrain from taking any action which is necessary to preserve, the
Option, or (iii) enter into any agreement, arrangement or commitment that would
derogate from or conflict with the rights granted to Artelo under this
Agreement.”

 

 

 

[***] Certain information in this document has been omitted because it is both
(i) not material and (ii) would be competitively harmful if publicly disclosed.
 

   

  

b.       Section 5.1.1 of the Agreement is hereby amended and restated to read
in its entirety as follows:

 

“5.1.1  Equity Grant.  As partial consideration for the grant of the Option by
NEOMED to Artelo and the supply of the Technology Transfer Materials, Artelo
shall grant NEOMED (a) on the Effective Date, 120,000 fully paid and
non-assessable shares of Artelo’s common stock subject to Artelo and NEOMED then
executing a Common Stock Purchase Agreement in substantially the form attached
hereto as Exhibit D (the “Purchase Agreement”), and (b) (i) within ten (10)
business days following the consummation of a public offering of Artelo’s common
stock prior to April 25, 2019, that number of fully paid non-assessable shares
of Artelo’s common stock equal to One Hundred Thousand Dollars (US$100,000)
divided by the price per share of common stock in such public offering, or (ii)
if Artelo has not consummated a public offering of its common stock prior to
April 25, 2019, then within ten (10) business days following April 25, 2019,
that number of fully paid non-assessable shares of Artelo’s common stock equal
to One Hundred Thousand Dollars (US$ 100,000) divided by the closing bid price
of Artelo’s common stock as shown on the OTCQB Venture Market as of April 25,
2019, subject to in each case, as applicable, Artelo and NEOMED then executing a
Common Stock Purchase Agreement in substantially the form attached hereto as
Exhibit F (the “Second Purchase Agreement”).  To the extent of any conflict
between the terms of this Section 5.1.1 and the Purchase Agreement or the Second
Purchase Agreement, the terms and conditions of the Purchase Agreement or the
Second Purchase Agreement, as applicable, shall control and be determinative.”

 

c.       Section 5.1.2 of the Agreement is hereby amended and restated to read
in its entirety as follows:

 

“5.1.2  Cash Consideration.  As partial consideration for the grant of the
Option by NEOMED to Artelo and the supply of the Technology Transfer Materials,
Artelo shall make the following payments to NEOMED:  (a) [***] due on the
Effective Date, (b) [***], and (c) [***]; provided that if any of the foregoing
payments have not accrued and become due prior to the earlier to occur of (i)
the exercise of the Option by Artelo, and (ii) termination of this Agreement by
Artelo pursuant to Section 12.2 hereof, then Artelo’s payment obligations with
respect to such payments that have not accrued and become due shall be
extinguished and become null and void.”

 

d.       A new Section 5.1.3 is added to the Agreement as follows:

 

“5.1.3  Additional Cash Consideration.  As partial consideration for the grant
of the Option by NEOMED to Artelo and the supply of the Technology Transfer
Materials, Artelo shall make an investment of no less than [***], which shall be
used by Artelo exclusively for the synthesis of the Compound to be used for
clinical studies.

 

e.       The Second Purchase Agreement attached to this Amendment is hereby
added to the Agreement as Exhibit F.

 

 

 

[***] Certain information in this document has been omitted because it is both
(i) not material and (ii) would be competitively harmful if publicly disclosed.
 

   

  

2.       No Other Modifications.  Except as specifically provided in this
Amendment, the terms and conditions of the Agreement remain in full force and
effect. No provisions of this Amendment may be modified or amended except
expressly in a writing signed by both parties, nor shall any terms be waived
except expressly in a writing signed by the Party charged therewith.

 

3.       Counterparts.  This Amendment may be executed in any number of
counterparts, each of which shall be deemed to be an original, but all of which
together shall constitute one and the same instrument. 

 

[Signature Page Follows.]

 

 

 

[***] Certain information in this document has been omitted because it is both
(i) not material and (ii) would be competitively harmful if publicly disclosed.

 

   

 

IN WITNESS WHEREOF, the Parties hereto have duly executed this Amendment as of
the Amendment Effective Date.

 

 

NEOMED INSTITUTE

        By /s/ Donald Olds

 

 

Donald Olds, President & CEO           ARTELO BIOSCIENCES, INC.  

 

 

 

 

 

By

/s/ Gregory D. Gorgas

 

 

 

Gregory D. Gorgas, President & CEO

 

  

[Signature Page to First Amendment to Material and Data Transfer, Option and
License Agreement]

 

 

 

[***] Certain information in this document has been omitted because it is both
(i) not material and (ii) would be competitively harmful if publicly disclosed.